Author/Authors :
Gounder، نويسنده , , Murugesan K. and Sun، نويسنده , , Show-Li and Sands، نويسنده , , Howard and Lin، نويسنده , , Yong and Shih، نويسنده , , Weichung J. and Gu، نويسنده , , Zheming and Charles-Williams، نويسنده , , Samantha and Roychowdhury، نويسنده , , Moulakshi and Rajendra، نويسنده , , Rajeev and Rubin، نويسنده , , Eric H.، نويسنده ,
Abstract :
9-Nitrocamptothecin (9-NC) is an orally administered camptothecin (CPT) that is under evaluation in clinical trials. This compound is not fluorescent, which has hampered development of a sensitive high-performance liquid chromatographic (LC) assay for measurement of drug concentrations in clinical trials. We now report development of an assay that involves reduction of 9-NC to the fluorescent compound 9-aminocamptothecin (9-AC). The method is based on enzymatic reduction of 9-NC using bovine liver S-9 fraction. This method is validated to quantitate 9-NC and 9-AC in patient samples, and yields results comparable to those obtained with an LC/MS method.
